AR013005A1 - Compuestos derivados de la fenil-y aminofenil-alquilsulfonamida y urea, su empleo, un procedimiento para prepararlos, composiciones farmaceuticas que loscomprenden, compuestos utiles como intermediarios - Google Patents
Compuestos derivados de la fenil-y aminofenil-alquilsulfonamida y urea, su empleo, un procedimiento para prepararlos, composiciones farmaceuticas que loscomprenden, compuestos utiles como intermediariosInfo
- Publication number
- AR013005A1 AR013005A1 ARP980102929A ARP980102929A AR013005A1 AR 013005 A1 AR013005 A1 AR 013005A1 AR P980102929 A ARP980102929 A AR P980102929A AR P980102929 A ARP980102929 A AR P980102929A AR 013005 A1 AR013005 A1 AR 013005A1
- Authority
- AR
- Argentina
- Prior art keywords
- lower alkyl
- phenyl
- proviso
- compounds
- alkylsulfonamide
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 title abstract 2
- 239000004202 carbamide Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical group C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 abstract 2
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 abstract 2
- IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical group C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000032841 Bulimia Diseases 0.000 abstract 1
- 206010006550 Bulimia nervosa Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 206010028735 Nasal congestion Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010039966 Senile dementia Diseases 0.000 abstract 1
- 206010046543 Urinary incontinence Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000004450 alkenylene group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 208000022531 anorexia Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 206010061428 decreased appetite Diseases 0.000 abstract 1
- 230000006735 deficit Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 201000011264 priapism Diseases 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- CBDKQYKMCICBOF-UHFFFAOYSA-N thiazoline Chemical group C1CN=CS1 CBDKQYKMCICBOF-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D233/22—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D233/24—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/44—Nitrogen atoms not forming part of a nitro radical
- C07D233/50—Nitrogen atoms not forming part of a nitro radical with carbocyclic radicals directly attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/28—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Otolaryngology (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Compuestos derivados de la fenil- y amino fenil-alquilsulfonamida y urea representados por la formula (I): en donde A es R1q(R3R60N)m; m y q son cadauno 0 o 1, con la condicion de que cuando q es 1, m es 0 y cuando q es 0, m es 1; Z es C=O o SO2;n es 1 con la condicion de que cuando Z es C=O, m es 1; X es-NH-, -CH2- o -OCH2-; y es 2- imidazolina, 2-oxazolina, 2 tiazolina o 4 -imidazol; R1 es H, alquilo inferior o fenilo, conla condicion de que cuando R1 es H, m es 1; R2, R3 y R60 son cada uno independientemente H, alquilo inferior o fenilo; R4 R5 R6 y R7 son cada unoindependientemente hidrogeno, alquilo inferior, -CF3, alcoxilo inferior, halogeno, fenilo, alquenilo inferior, hidroxilo, (alquilo inferior) sulfonamidoo cicloalquilo inferior, en donde R2 y R7 opcionalmente pueden ser tomados juntos para formar un alquileno o alquenileno de 2 a 3 átomos de carbono en unanillo de 5 o 6 miembros sin sustituir y opcionalmente sustituidos, en donde los sustituyentes opcionales en el anillo son halo, alquilo inferior, o -CH,con la condicion de que cuando R7 es hidroxilo o (alquilo inferior) sulfonamido, entonces X no es -NH- cuando Y es 2-imidazolina. Los compuestosincluyen las sales farmacéuticamente aceptables de las anteriores. En la formula anterior A puede ser, por ejemplo: (R1SO2NR2-), (R3R60NSO2NR2-), o(R3R60NCONR2-). El empleo de los compuestos anteriores y composiciones que los contienen como alfa1A/1L agonistas en eltratamiento de varios estados deenfermedad tales como la incontinencia urinaria, congestion nasal, priapismo, depresion, ansiedad, demencia, senilidad, deficiencias de la atencion yrazonamiento de la enfermedad de Alzheimer, y trastornos de la alimentacion como obesidad, bulimia y anorexia. También se describe un procedimiento e
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5047997P | 1997-06-23 | 1997-06-23 | |
| US7597898P | 1998-02-25 | 1998-02-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR013005A1 true AR013005A1 (es) | 2000-11-22 |
Family
ID=26728313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980102929A AR013005A1 (es) | 1997-06-23 | 1998-06-19 | Compuestos derivados de la fenil-y aminofenil-alquilsulfonamida y urea, su empleo, un procedimiento para prepararlos, composiciones farmaceuticas que loscomprenden, compuestos utiles como intermediarios |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US5952362A (es) |
| EP (1) | EP0887346B1 (es) |
| JP (1) | JP2977536B2 (es) |
| KR (1) | KR100608501B1 (es) |
| CN (3) | CN1262547C (es) |
| AR (1) | AR013005A1 (es) |
| AT (1) | ATE380793T1 (es) |
| AU (1) | AU713068C (es) |
| BR (1) | BR9802201B1 (es) |
| CA (3) | CA2418778C (es) |
| CO (1) | CO4940479A1 (es) |
| CZ (1) | CZ197498A3 (es) |
| DE (1) | DE69838829T2 (es) |
| ES (1) | ES2297870T3 (es) |
| HR (1) | HRP980353A2 (es) |
| HU (1) | HUP9801357A3 (es) |
| ID (1) | ID20463A (es) |
| IL (2) | IL124839A (es) |
| MA (1) | MA26515A1 (es) |
| MY (1) | MY128048A (es) |
| NO (1) | NO310868B1 (es) |
| NZ (1) | NZ330506A (es) |
| PE (1) | PE85999A1 (es) |
| PL (1) | PL198053B1 (es) |
| RU (1) | RU2218335C2 (es) |
| SG (1) | SG72827A1 (es) |
| TR (1) | TR199801197A2 (es) |
| TW (1) | TW517049B (es) |
| UY (1) | UY25057A1 (es) |
| YU (1) | YU26498A (es) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6407132B1 (en) * | 1997-07-25 | 2002-06-18 | James Black Foundation Limited | Substituted imidazole derivatives and their use as histamine H3 receptor ligands |
| DE19824175A1 (de) * | 1998-05-29 | 1999-12-02 | Novartis Ag | Amino-azol-Verbindungen |
| US20030073850A1 (en) * | 1998-08-07 | 2003-04-17 | Altenbach Robert J. | 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use |
| US6503935B1 (en) * | 1998-08-07 | 2003-01-07 | Abbott Laboratories | Imidazoles and related compounds as α1A agonists |
| US6395758B1 (en) * | 1998-08-14 | 2002-05-28 | Gpi Nil Holdings, Inc. | Small molecule carbamates or ureas for vision and memory disorders |
| GB9910110D0 (en) * | 1999-04-30 | 1999-06-30 | Glaxo Group Ltd | Chemical compounds |
| US20020183357A1 (en) * | 2000-02-17 | 2002-12-05 | Brioni Jorge D. | Use of alpha- 1- alpha adrenoceptor agonists with alpha-1-Beta antagonism for the treatment of stress urinary incontinence |
| US6323231B1 (en) | 2000-02-17 | 2001-11-27 | Abbott Laboratories | Use of α1A adrenoceptor agonists with α1B and α1D antagonism for the treatment of stress urinary incontinence |
| AU2001259536A1 (en) * | 2000-05-10 | 2001-11-20 | The Cleveland Clinic Foundation | Model systems for neurodegenerative and cardiovascular disorders |
| AU2001286557A1 (en) * | 2000-08-23 | 2002-03-04 | Merck Frosst Canada And Co. | Method of treating or preventing urinary incontinence using prostanoid ep1 receptor antagonists |
| EP1341529A2 (en) * | 2000-11-10 | 2003-09-10 | F. Hoffman-la Roche AG | Hydrolytically unstable compositions |
| US20020169193A1 (en) * | 2001-02-10 | 2002-11-14 | Pascale Pouzet | Alkylphenyliminoimidazolidine derivatives for treating urinary incontinence |
| DE10106214A1 (de) * | 2001-02-10 | 2002-08-14 | Boehringer Ingelheim Pharma | Neue Alkyl-phenylimino-imidazolidin-Derivate zur Behandlung der Harninkontinenz |
| US20040170689A1 (en) * | 2001-11-09 | 2004-09-02 | Odink Debra Alida | Stabilized formulations comprising hydrolytically unstable compositions |
| EP1333028A1 (en) * | 2002-01-31 | 2003-08-06 | Boehringer Ingelheim Pharma GmbH & Co.KG | 2'-Halo-3',5'-dialkoxyphen-1'-yl-imino-2-imidazolidine derivatives and the use thereof for the treatment of urinary incontinence |
| US6703409B2 (en) | 2002-01-31 | 2004-03-09 | Boehringer Ingelheim Pharma Gmbh & Co Kg | 2′-Halo-3′,5′-dialkoxyphen-1′-yl-imino-2-imidazolidine and the use thereof as a drug |
| PL373410A1 (en) * | 2002-02-01 | 2005-08-22 | F.Hoffman-La Roche Ag | Substituted indoles as alpha-1 agonists |
| PL373322A1 (en) * | 2002-04-23 | 2005-08-22 | F.Hoffmann-La Roche Ag | Imidazolinylmethyl aralkylsulfonamides |
| EP1660484B1 (en) * | 2003-05-09 | 2008-08-27 | F. Hoffmann-La Roche Ag | Methyl indoles and methyl pyrrolopyridines as alpha-1 adrenergic agonists |
| US20060258986A1 (en) * | 2005-02-11 | 2006-11-16 | Hunter Ian W | Controlled needle-free transport |
| PE20070341A1 (es) * | 2005-07-29 | 2007-04-13 | Wyeth Corp | Derivados de pirrol como moduladores del receptor de progesterona |
| PE20070182A1 (es) * | 2005-07-29 | 2007-03-06 | Wyeth Corp | Derivados cianopirrol-fenil amida como moduladores del receptor de progesterona |
| GB0519294D0 (en) * | 2005-09-21 | 2005-11-02 | Karobio Ab | Compounds |
| WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| MX2010000617A (es) | 2007-07-17 | 2010-05-17 | Plexxikon Inc | Compuestos y metodos para modulacion de cinasa, e indicaciones de estos. |
| KR20100096262A (ko) * | 2008-02-04 | 2010-09-01 | 에프. 호프만-라 로슈 아게 | 신규한 이미다졸리닐메틸 아릴 설폰아미드 |
| CN101925579A (zh) * | 2008-02-04 | 2010-12-22 | 霍夫曼-拉罗奇有限公司 | 新型的咪唑啉基甲基芳基磺酰胺 |
| JP4168086B1 (ja) * | 2008-04-16 | 2008-10-22 | 国立大学法人福井大学 | イミダゾリン誘導体 |
| EA022924B1 (ru) | 2009-04-03 | 2016-03-31 | Ф.Хоффманн-Ля Рош Аг | ТВЁРДАЯ ФОРМА {3-[5-(4-ХЛОРФЕНИЛ)-1Н-ПИРРОЛО[2,3-b]ПИРИДИН-3-КАРБОНИЛ]-2,4-ДИФТОРФЕНИЛ}АМИДА ПРОПАН-1-СУЛЬФОНОВОЙ КИСЛОТЫ И ЕЁ ПРИМЕНЕНИЕ |
| US8329724B2 (en) | 2009-08-03 | 2012-12-11 | Hoffmann-La Roche Inc. | Process for the manufacture of pharmaceutically active compounds |
| NZ629615A (en) | 2009-11-06 | 2016-01-29 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| SI2672967T1 (sl) | 2011-02-07 | 2018-12-31 | Plexxikon Inc. | Spojine in postopki za kinazno modulacijo in indikacije zanjo |
| AR085279A1 (es) | 2011-02-21 | 2013-09-18 | Plexxikon Inc | Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico |
| US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
| TW201603707A (zh) * | 2014-06-24 | 2016-02-01 | 陶氏農業科學公司 | 具有特定殺蟲效用之分子及與其相關之中間物、組成物和製程 |
| CN106543077B (zh) * | 2016-10-27 | 2019-08-23 | 西安交通大学 | N,n’-双取代芳基硫脲衍生物及其合成方法和应用 |
| CN106905181B (zh) * | 2017-04-14 | 2018-10-09 | 上海海洋大学 | 一种立达霉代谢产物16的合成方法 |
| CN108863818A (zh) * | 2018-06-28 | 2018-11-23 | 江苏新瑞药业有限公司 | 一种对氨基间甲酚的合成方法 |
| CN109651289B (zh) * | 2018-12-18 | 2022-08-09 | 五邑大学 | 一种3-噻唑啉化合物及其合成方法和应用 |
| EP3958851B1 (en) * | 2019-04-23 | 2024-08-14 | The Cleveland Clinic Foundation | Allosteric activators of the alpha ia-adrenergic receptor |
| EP4048263A4 (en) * | 2019-10-25 | 2023-11-15 | Curasen Therapeutics, Inc. | METHOD FOR TREATING NEURONOLOGICAL DISORDERS USING PARTIAL ALPHA 1A-AR AGONISTS |
| JP2023541375A (ja) * | 2020-08-27 | 2023-10-02 | キュラセン セラピューティクス インコーポレイテッド | α１Ａ－アドレナリン受容体アゴニスト及び使用方法 |
| WO2024166131A1 (en) | 2023-02-09 | 2024-08-15 | Satyarx Pharma Innovations Private Limited | Heteroaryl compounds as pkmyt1 inhibitors |
| CN117447364A (zh) * | 2023-10-17 | 2024-01-26 | 长沙贝塔医药科技有限公司 | 一种同位素标记合成对溴氰甲基苯磺酸酯-13c的方法及应用 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE135016C (es) * | ||||
| US2663732A (en) * | 1950-04-29 | 1953-12-22 | Eastman Kodak Co | (alkysulfonamido) arylhydrazines |
| DE1151331B (de) * | 1957-11-15 | 1963-07-11 | Bayer Ag | Verfahren zur Herstellung metallhaltiger Monoazofarbstoffe |
| AT241435B (de) * | 1963-06-11 | 1965-07-26 | Chemie Linz Ag | Verfahren zur Herstellung von neuen Phenylalkanolaminderivaten und deren Salzen |
| ES323985A1 (es) * | 1966-02-26 | 1966-12-16 | Blade Pique Juan | Procedimiento para la obtenciën de derivados del imidazol |
| GB1592649A (en) * | 1976-12-20 | 1981-07-08 | Wellcome Found | Imidazoline derivatives and their use as pesticides |
| FR2373967A1 (fr) * | 1976-12-20 | 1978-07-13 | Wellcome Found | Derives de l'imidazoline et leur emploi comme agents pesticides |
| CH632268A5 (de) * | 1977-01-14 | 1982-09-30 | Sandoz Ag | Verfahren zur herstellung von neuen heterocyclylaminoderivaten. |
| IL55800A (en) * | 1977-10-26 | 1982-05-31 | Wellcome Found | Imidazoline derivatives,their preparation and their use as arthropodicides |
| CA1138451A (en) * | 1979-04-03 | 1982-12-28 | Ikuo Ueda | 2-imidazoline derivatives, process for the preparation thereof and the pharmaceutical composition of the same |
| US4343808A (en) * | 1979-10-25 | 1982-08-10 | The Dow Chemical Company | Method of inhibiting sickling of sickle erythrocytes |
| EP0043659B1 (en) * | 1980-07-09 | 1985-02-06 | Beecham Group Plc | Clonidine derivatives useful in the treatment of diarrhoea |
| FR2521140A1 (fr) * | 1982-02-05 | 1983-08-12 | Synthelabo | Derives d'imidazolidine, leur preparation et leur application en therapeutique |
| FR2549049B1 (fr) * | 1983-07-13 | 1986-06-20 | Chauvin Blache Lab | Nouvelles amidines, leur procede de preparation et leur application therapeutique |
| HU192986B (en) * | 1984-05-23 | 1987-08-28 | Egyt Gyogyszervegyeszeti Gyar | Process for production of imidasodiline derivatives |
| US4665095A (en) * | 1985-12-11 | 1987-05-12 | Abbott Laboratories | Use of 2-[(3,5-dihalo-4-aminobenzyl)]imidazolines to stimulate alpha-1 adrenergic receptors and to treat nasal congestion |
| US4956388A (en) * | 1986-12-22 | 1990-09-11 | Eli Lilly And Company | 3-aryloxy-3-substituted propanamines |
| DE3842798A1 (de) * | 1988-12-20 | 1990-06-21 | Hoechst Ag | Imidazolinderivate enthaltende mittel zur wirtstiersystemischen bekaempfung von ektoparasiten sowie neue imidazolinderivate |
| PT95899A (pt) * | 1989-11-17 | 1991-09-13 | Glaxo Group Ltd | Processo para a preparacao de derivados indole |
| US5360822A (en) * | 1990-02-07 | 1994-11-01 | Nippon Shinyaku Co. Ltd. | Sulfonanilide derivatives and medicine |
| MX24595A (es) * | 1990-06-29 | 1993-09-01 | Sumitomo Chemical Co | Derivados de fenilimidazol y procedimiento para supreparacion. |
| US5389650A (en) * | 1991-09-30 | 1995-02-14 | Merck Frosst Canada, Inc. | (Azaarylmethoxy)indoles as inhibitors of leukotriene biosynthesis |
| AU3488693A (en) * | 1992-02-13 | 1993-09-03 | Merck Frosst Canada Inc. | (Azaaromaticalkoxy)indoles as inhibitors of leukotriene biosynthesis |
| CA2145182C (en) * | 1992-09-25 | 2001-09-18 | Jonathan A. Bard | Dna encoding human alpha 1 adrenergic receptors and uses thereof |
| WO1994008040A1 (en) * | 1992-09-25 | 1994-04-14 | Synaptic Pharmaceutical Corporation | Dna encoding human alpha 1 adrenergic receptors and uses thereof |
| US5578611A (en) * | 1992-11-13 | 1996-11-26 | Synaptic Pharmaceutical Corporation | Use of α-1C specific compounds to treat benign prostatic hyperplasia |
| US5403847A (en) * | 1992-11-13 | 1995-04-04 | Synaptic Pharmaceutical Corporation | Use of α1C specific compounds to treat benign prostatic hyperlasia |
| HUT74386A (en) * | 1993-11-15 | 1996-12-30 | Schering Corp | Phenyl-alkyl imidazoles as h3-receptor antagonists and pharmaceutical compositions containing them |
| US5576437A (en) * | 1993-12-17 | 1996-11-19 | The Procter & Gamble Company | 7-(2-imidazolnylamino) quinoline compounds useful as alpha-2 adrenoceptor agonists |
| US5478858A (en) * | 1993-12-17 | 1995-12-26 | The Procter & Gamble Company | 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists |
| US5616601A (en) * | 1994-07-28 | 1997-04-01 | Gd Searle & Co | 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation |
| EP0775134A4 (en) * | 1994-08-04 | 1997-08-13 | Synaptic Pharma Corp | NEW BENZIMIDAZOLE DERIVATIVES |
| AU4176396A (en) * | 1994-12-08 | 1996-06-26 | Knoll Aktiengesellschaft | Use of substituted phenylamidine and phenylguanidine compounds for the treatment of cerebral and cardiac ischaemia, convulsion and sickle cell anaemia |
| US5597823A (en) * | 1995-01-27 | 1997-01-28 | Abbott Laboratories | Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic antagonists |
| DE19514579A1 (de) * | 1995-04-20 | 1996-10-24 | Boehringer Ingelheim Kg | Verwendung von alpha¶1¶¶L¶-Agonisten zur Behandlung der Harninkontinenz |
| US5610174A (en) * | 1995-06-02 | 1997-03-11 | Synaptic Pharmaceutical Corporation | Use of α1A -selective adrenoceptor agonists for the treatment of urinary incontinence |
| WO1996038143A1 (en) * | 1995-06-02 | 1996-12-05 | Synaptic Pharmaceutical Corporation | The use of alpha-1c-selective adrenoceptor agonists for the treatment of urinary incontinence |
| US5677321A (en) * | 1996-02-29 | 1997-10-14 | Synaptic Pharmaceutical Corporation | 5- and 6-(2-imidazolin-2-ylamino) and -(2-thiazolin-2-ylamino)-benzothiazoles as alpha-2 adrenergic ligands |
| JP2000506904A (ja) * | 1996-05-16 | 2000-06-06 | シナプティック・ファーマスーティカル・コーポレーション | ジヒドロピリミジン類およびその使用 |
-
1998
- 1998-05-18 SG SG1998001348A patent/SG72827A1/en unknown
- 1998-05-25 NZ NZ330506A patent/NZ330506A/xx unknown
- 1998-06-03 US US09/089,779 patent/US5952362A/en not_active Expired - Lifetime
- 1998-06-05 CA CA002418778A patent/CA2418778C/en not_active Expired - Fee Related
- 1998-06-05 CA CA002240136A patent/CA2240136C/en not_active Expired - Fee Related
- 1998-06-05 CA CA002430623A patent/CA2430623A1/en not_active Abandoned
- 1998-06-10 IL IL12483998A patent/IL124839A/en not_active IP Right Cessation
- 1998-06-12 AT AT98110822T patent/ATE380793T1/de active
- 1998-06-12 EP EP98110822A patent/EP0887346B1/en not_active Expired - Lifetime
- 1998-06-12 ES ES98110822T patent/ES2297870T3/es not_active Expired - Lifetime
- 1998-06-12 DE DE69838829T patent/DE69838829T2/de not_active Expired - Lifetime
- 1998-06-12 ID IDP980873A patent/ID20463A/id unknown
- 1998-06-17 HU HU9801357A patent/HUP9801357A3/hu unknown
- 1998-06-18 YU YU26498A patent/YU26498A/sh unknown
- 1998-06-19 MY MYPI98002785A patent/MY128048A/en unknown
- 1998-06-19 JP JP10172403A patent/JP2977536B2/ja not_active Expired - Fee Related
- 1998-06-19 AR ARP980102929A patent/AR013005A1/es not_active Application Discontinuation
- 1998-06-19 NO NO19982884A patent/NO310868B1/no not_active IP Right Cessation
- 1998-06-19 CO CO98035130A patent/CO4940479A1/es unknown
- 1998-06-19 UY UY25057A patent/UY25057A1/es unknown
- 1998-06-22 PE PE1998000547A patent/PE85999A1/es not_active Application Discontinuation
- 1998-06-22 CN CNB031386059A patent/CN1262547C/zh not_active Expired - Fee Related
- 1998-06-22 PL PL326959A patent/PL198053B1/pl not_active IP Right Cessation
- 1998-06-22 CZ CZ981974A patent/CZ197498A3/cs unknown
- 1998-06-22 CN CNA031264069A patent/CN1515559A/zh active Pending
- 1998-06-22 AU AU73102/98A patent/AU713068C/en not_active Ceased
- 1998-06-22 KR KR1019980023417A patent/KR100608501B1/ko not_active Expired - Fee Related
- 1998-06-22 RU RU98111769/04A patent/RU2218335C2/ru not_active IP Right Cessation
- 1998-06-22 CN CNB981152090A patent/CN1176910C/zh not_active Expired - Fee Related
- 1998-06-22 MA MA25130A patent/MA26515A1/fr unknown
- 1998-06-23 TR TR1998/01197A patent/TR199801197A2/xx unknown
- 1998-06-23 TW TW087110098A patent/TW517049B/zh not_active IP Right Cessation
- 1998-06-23 BR BRPI9802201-6A patent/BR9802201B1/pt not_active IP Right Cessation
- 1998-06-23 HR HR60/075,978A patent/HRP980353A2/hr not_active Application Discontinuation
-
1999
- 1999-03-08 US US09/264,467 patent/US6057349A/en not_active Expired - Fee Related
-
2003
- 2003-09-04 IL IL15774503A patent/IL157745A0/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR013005A1 (es) | Compuestos derivados de la fenil-y aminofenil-alquilsulfonamida y urea, su empleo, un procedimiento para prepararlos, composiciones farmaceuticas que loscomprenden, compuestos utiles como intermediarios | |
| ATE28864T1 (de) | Amide-derivate. | |
| SE7714184L (sv) | Piperazinderivat | |
| ES466366A1 (es) | Un procedimiento para preparar derivados de metasulfonamido-benzamida. | |
| ES8402696A1 (es) | Procedimiento para la preparacion de (halogeno) alcohil y -alcoxi-sulfonilureas substituidas con radicales heterociclicos. | |
| NO160783C (no) | Analogifremgangsmaate til fremstilling av terapeutisk aktive substituerte beta-karbolinderivater. | |
| DK543886A (da) | Phenoxysubstituerede beta-carbolinderivater, deres fremstilling ogderes anvendelse som laegemiddel | |
| DE3876536D1 (de) | Oxadiazol-pyrimidinone, ihre herstellung und ihre kosmetische und dermopharmazeutische verwendung. | |
| NO160445C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive heterocykliske forbindelser. | |
| ECSP982550A (es) | Derivados de fenil y aminofenil - alquilsulfonamidas y urea | |
| PL245746A1 (en) | Process for preparing 2-hydroxymethyl-6-methyl-4-p-thiolyl-4,5,6,7-tetrahydro-theino/2,3-c/-pyridine | |
| TH45373A (th) | อนุพันธ์ฟินิล และอะมิโนฟินิลอัลคิล ซัลโฟนาไมด์และยูเรีย | |
| FI803970L (fi) | Nya substituerade 4-amino-2,6-diaryl-tetrahydrotiopyraner deras syraadditionssalter deras framstaellningsfoerfarande deras anvaendning och farmaceutiska blandningar | |
| MX9707911A (es) | Derivados de amina 1-[w-(3,4-dihidro-2-naftalenil)alquil]- ciclica, proceso para su preparacion y composiciones farmaceuticas que contienen los mismos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |